Affectis Pharmaceuticals
Developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2010 | 2011 | 2012 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 531 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (1096 %) | - | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Affectis is a biopharmaceutical company focused on the development of novel drugs aimed at treating psychiatric and inflammatory disorders. The company operates in the pharmaceutical and healthcare market, targeting conditions that have significant unmet medical needs. Affectis serves a diverse range of clients, including healthcare providers, hospitals, and research institutions. The business model revolves around the research, development, and commercialization of pharmaceutical products. Revenue is generated through the sale of these drugs, as well as potential licensing agreements and partnerships with other pharmaceutical companies. The company leverages its expertise in biopharmaceuticals to bring innovative treatments to market, addressing critical health issues and improving patient outcomes.
Keywords: biopharmaceutical, novel drugs, psychiatric disorders, inflammatory disorders, healthcare, pharmaceutical market, research, development, commercialization, patient outcomes.